SELLAS Life Sciences Group, Inc. (SLS) Form 10-Q — May 12, 2026
SELLAS Life Sciences Group, Inc. (SLS) reported a net loss of $8.4 million for the three months ended March 31, 2026, compared to a net loss of $5.8 million for the same period in 2025. The increase in net loss is primarily due to higher research and development expenses as the company prepares for a potential Biologics License Application (BLA) filing for its lead product candidate, GPS. The company received $44.1 million from the exercise of 28.2 million outstanding warrants at a weighted average exercise price of $1.56 per share during the three months ended March 31, 2026.
Key figures
- Eps
- -0.05
- Eps Beat
- 0
- Revenue
- 0
- Net Income
- -8,407
- Total Debt
- 0
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 114,177
- Cash Position
- 107,197
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 181,332,574
- Warrant Exercise Proceeds
- 44,150
- Upfront Payments From3 DMedicines
- 10,500
- Subsequent Warrant Exercise Proceeds
- 7,500
- Potential Future Milestones From3 DMedicines
- 191,500
Price after filing
Close on the filing date to close N calendar days later (from $5.22). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.